SS18–SSX (formerly called SYT–SSX) fusion gene has been established clinicallyas a molecular diagnostic test for synovial sarcoma, but the prognostic value of the fusion gene variant for survival is controversial. This evidence concerns the gene SSX2 and synovial sarcoma.